High-throughput screening and biophysical interrogation of hepatotropic AAV

Molecular Therapy

Volumn 16, Issue 12, 2008, Pages 1960-1967

  Murphy, Samuel L ^a   Bhagwat, Anand ^b   Edmonson, Shyrie ^c   Zhou, Shangzhen ^a   High, Katherine A ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN A; CYCLIN DEPENDENT KINASE 2;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ARTICLE; BIOPHYSICS; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIVER; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN INTERACTION; SEROTYPE; THERMOSTABILITY; VIRAL GENE DELIVERY SYSTEM;

ANTIBODIES, MONOCLONAL; BIOPHYSICS; CAPSID PROTEINS; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; DEPENDOVIRUS; GENETIC VECTORS; GENOME, VIRAL; KINETICS; LIVER; PROTEIN BINDING;

ADENO-ASSOCIATED VIRUS;

EID: 56749177117     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.210     Document Type: Article

References (39)

1. Warrington, KH Jr and Herzog, RW (2006). Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 119: 571-603.
2. Schmidt, M, Voutekakis, A, Afione, S, Zheng, C, Mandikian, JD and Chiorini, JA (2008). Adeno-associated virus type 12 (AAV12): A novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J Virol 82: 1399-1406.
3. Gao, G, Vandenberghe, LH and Wilson, JM (2005). New recombinant serotypes of AAV vectors. Curr Gene Ther 5: 285-297.
4. Wu, Z, Asokan, A and Samulski, RJ (2006). Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol Ther 14 316-327.
5. Cearley, CN and Wolfe, JH (2006). Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13: 528-537.
6. Allocca, M, Mussolino, C, Garcia-Hoyos, M, Sanges, D, Iodice, C, Petrillo, M et al. (2007). Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol 81: 11372-11380.
7. Jiang, H, Lillicrap, D, Pataroyo-White, S, Liu, T, Qian, X, Scallan, CD et al. (2006). Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108: 107-115.
8. Davidoff, AM, Gray, JT, Ng, CY, Zhang, Y, Zhou, J, Spence, Y et al. (2005). Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 11: 875-888.
9. Thomas, CE, Storm, TA, Huang, Z and Kay, MA (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 78: 3110-3122.
10. Kashiwakura, Y, Tamayose, K, Iwabuchi, K, Hirai, Y, Shimada, T, Matsumoto, K et al. (2005). Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 79: 609-614.
11. Qing, K, Mah, C, Hansen, J, Zhou, S, Dwarki, V, Srivastava, A et al. (1999). Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5: 71-77.
12. Summerford, C, Bartlett, JS and Samulski, RJ (1999). αVβ5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med 5: 78-82.
13. Summerford, C and Samulski, RJ (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438-1445.
14. Akache, B, Grimm, D, Pandey, K, Yant, SR, Xu, H, Kay, MA (2006). The 37/ 67-kDa laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80: 9831-9836.
15. Xie, Q, Bu, W, Bhatia, S, Hare, J, Somasundaram, T, Azzi, A et al. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 99: 10405-10410.
16. Nam, HJ, Lane, MD, Padron, E, Gurda, B, McKenna, R, Kohlbrenner, E et al. (2007). Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol 81: 12260-12271.
17. Akache, B, Grimm, D, Shen, X, Fuess, S, Yant, SR, Glazer, DS et al. (2007). A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol Ther 15: 330-339.
18. Wobus, CE, Hugle-Dorr, B, Girod, A, Petersen, G, Hallek, M and Kleinschmidt, JA (2000). Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol 74: 9281-9293.
19. Bleker, S, Pawlita, M and Kleinschmidt, JA (2006). Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging. J Virol 80: 810-820.
20. Grieger, JC, Snowdy, S and Samulski, RJ (2006). Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J Virol 80: 5199-5210.
21. Grimm, D, Kern, A, Rittner, K and Kleinschmidt, JA (1998). Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 9: 2745-2760.
22. Kronenberg, S, Bottcher, B, von der Lieth, CW, Bleker, S and Kleinschmidt, JA (2005). A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol 79: 5296-5303.
23. Lane, ME, Yu, B, Rice, A, Lipson, KE, Liang, C, Sun, L et al. (2001). A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 61: 6170-6177.
24. Saudan, P, Vlach, J and Beard, P (2000). Inhibition of S-phase progression by adeno-associated virus Rep78 protein is mediated by hypophosphorylated pRb. EMBO J 19: 4351-4361.
25. Berthet, C, Raj, K, Saudan, P and Beard, P (2005). How adeno-associated virus Rep78 protein arrests cells completely in S phase. Proc Natl Acad Sci USA 102: 13634-13639.
26. Adams, PD, Sellers, WR, Sharma, SK, Wu, AD, Nalin, CM and Kaelin, WG Jr. (1996). Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol 16: 6623-6633.
27. Chen, YN, Sharma, SK, Ramsey, TM, Jiang, L, Martin, MS, Baker, K et al. (1999). Selective killing of transformed cells by cyclin/ cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 96: 4325-4329.
28. Mendoza, N, Fong, S, Marsters, J, Koeppen, H, Schwall, R, Wickramasinghe, D (2003). Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res 63: 1020-1024.
29. Castanedo, G, Clark, K, Wang, S, Tsui, V, Wong, M, Nicholas, J et al. (2006). CDK2/cyclinA inhibitors: Targeting the cyclinA recruitment site with small molecules derived from peptide leads. Bioorg Med Chem Lett 16: 1716-1720.
30. Clayton, RF, Rinaldi, A, Kandyba, EE, Edward, M, Willberg, C, Klenerman, P et al. (2005). Liver cell lines for the study of hepatocyte functions and immunological response. Liver Int 25: 389-402.
31. DiPasquale, G, Davidson, BL, Stein, CS, Martins, I, Scudiero, D, Monks, A et al. (2003). Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9: 1306-1312.
32. Hermanns, J, Schulze, A, Jansen-Dürr, P, Kleinschmidt, JA, Schmidt, R and zur Hausen, H (1997). Infection of primary cells by adeno-associated virus type 2 results in a modulation of cell cycle-regulating proteins. J Virol 71: 6020-6027.
33. Grifman, M, Chen, NN, Gao, GP, Cathomen, T, Wilson, JM and Weitzman, MD (1999). Overexpression of cyclin A inhibits augmentation of recombinant adeno-associated virus transduction by the adenovirus E4orf6 protein. J Virol 73: 10010-10019.
34. Zhong, L, Li, B, Mah, CS, Govindasamy, L, Agbandje-McKenna, M, Cooper, M et al. (2008). Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 105: 7827-7832.
35. Ros, C, Baltzer, C, Mani, B and Kempf, C (2006). Parvovirus uncoating in vitro reveals a mechanism of DNA release without capsid disassembly and striking differences in encapsidated DNA stability. Virology 345: 137-147.
36. Murphy, SL and High, KA (2008). Gene therapy for haemophilia. Br J Haematol 140: 479-487.
37. Matsushita, T, Elliger, S, Elliger, C, Podsakoff, G, Villarreal, L, Kurtzman, GJ et al. (1998). Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 5: 938-945.
38. Murphy, SL, Li, H, Zhou, S, Schlachterman, A and High, KA (2008). Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. Mol Ther 16: 138-145.
39. Li, H, Murphy, SL, Giles-Davis, W, Edmonson, S, Xiang, Z, Li, Y et al. (2007). Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther 15: 792-800.